Microbiota as a mediator of cancer progression and therapy

Translational Research

Volumn 179, Issue , 2017, Pages 139-154

  Pope, Jillian L ^a   Tomkovich, Sarah ^a,b   Yang, Ye ^a   Jobin, Christian ^a,c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADVERSE DRUG REACTION; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; COLORECTAL CARCINOMA; DIET; DRUG EFFICACY; DYSBIOSIS; HOST PATHOGEN INTERACTION; HUMAN; INTESTINE FLORA; MICROFLORA; NONHUMAN; ORGANISMAL INTERACTION; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ANIMAL; DISEASE COURSE; IMMUNOLOGY; MICROBIOLOGY; NEOPLASMS; PATHOLOGY;

ANIMALS; CARCINOGENESIS; DIET; DISEASE PROGRESSION; DYSBIOSIS; HUMANS; MICROBIOTA; NEOPLASMS;

EID: 84994442818     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.07.021     Document Type: Review

References (123)

1. 1 Stratton, M.R., Campbell, P.J., Futreal, P.A., The cancer genome. Nature 458 (2009), 719–724.
2. 2 Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A., Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
3. 3 Garraway, L.A., Lander, E.S., Lessons from the cancer genome. Cell 153 (2013), 17–37.
4. 4 Anand, P., Kunnumakkara, A.B., Sundaram, C., et al. Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25 (2008), 2097–2116.
5. 5 Dewhirst, F.E., Chen, T., Izard, J., et al. The human oral microbiome. J Bacteriol 192 (2010), 5002–5017.
6. 6 Whiteside, S.A., Razvi, H., Dave, S., Reid, G., Burton, J.P., The microbiome of the urinary tract–a role beyond infection. Nat Rev Urol 12 (2015), 81–90.
7. 7 Canny, G.O., McCormick, B.A., Bacteria in the intestine, helpful residents or enemies from within?. Infect Immun 76 (2008), 3360–3373.
8. 8 Spor, A., Koren, O., Ley, R., Unravelling the effects of the environment and host genotype on the gut microbiome. Nat Rev Microbiol 9 (2011), 279–290.
9. 9 Fujimura, K.E., Lynch, S.V., Microbiota in allergy and asthma and the emerging relationship with the gut microbiome. Cell Host Microbe 17 (2015), 592–602.
10. 10 Scher, J.U., Abramson, S.B., The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 7 (2011), 569–578.
11. 11 Tang, W.H., Hazen, S.L., The contributory role of gut microbiota in cardiovascular disease. J Clin Invest 124 (2014), 4204–4211.
12. 12 Ussar, S., Griffin, N.W., Bezy, O., et al. Interactions between gut microbiota, host genetics and diet modulate the predisposition to obesity and metabolic syndrome. Cell Metab 22 (2015), 516–530.
13. 13 Kallus, S.J., Brandt, L.J., The intestinal microbiota and obesity. J Clin Gastroenterol 46 (2012), 16–24.
14. 14 Borges-Canha, M., Portela-Cidade, J.P., Dinis-Ribeiro, M., Leite-Moreira, A.F., Pimentel-Nunes, P., Role of colonic microbiota in colorectal carcinogenesis: a systematic review. Rev Esp Enferm Dig 107 (2015), 659–671.
15. 15 De Martel, C., Ferlay, J., Franceschi, S., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 13 (2012), 607–615.
16. 16 Jobin, C., Colorectal cancer: looking for answers in the microbiota. Cancer Discov 3 (2013), 384–387.
17. 17 Marchesi, J.R., Dutilh, B.E., Hall, N., et al. Towards the human colorectal cancer microbiome. PLoS One, 6, 2011, e20447.
18. 18 Gao, Z., Guo, B., Gao, R., Zhu, Q., Qin, H., Microbiota disbiosis is associated with colorectal cancer. Front Microbiol, 6, 2015, 20.
19. 19 Feng, Q., Liang, S., Jia, H., et al. Gut microbiome development along the colorectal adenoma-carcinoma sequence. Nat Commun, 6, 2015, 6528.
20. 20 Zackular, J.P., Rogers, M.A., Ruffin, M.T., Schloss, P.D., The human gut microbiome as a screening tool for colorectal cancer. Cancer Prev Res (Phila) 7 (2014), 1112–1121.
21. 21 Narayanan, V., Peppelenbosch, M.P., Konstantinov, S.R., Human fecal microbiome-based biomarkers for colorectal cancer. Cancer Prev Res (Phila) 7 (2014), 1108–1111.
22. 22 Zeller, G., Tap, J., Voigt, A.Y., et al. Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol, 10, 2014, 766.
23. 23 Pevsner-Fischer, M., Tuganbaev, T., Meijer, M., et al. Role of the microbiome in non-gastrointestinal cancers. World J Clin Oncol 7 (2016), 200–213.
24. 24 Riley, D.R., Sieber, K.B., Robinson, K.M., et al. Bacteria-human somatic cell lateral gene transfer is enriched in cancer samples. PLoS Comput Biol, 9, 2013, e1003107.
25. 25 Yamamoto, M.L., Maier, I., Dang, A.T., et al. Intestinal bacteria modify lymphoma incidence and latency by affecting systemic inflammatory state, oxidative stress, and leukocyte genotoxicity. Cancer Res 73 (2013), 4222–4232.
26. 26 Witkowska, M., Smolewski, P., Helicobacter pylori infection, chronic inflammation, and genomic transformations in gastric MALT lymphoma. Mediators Inflamm, 2013, 2013, 523170.
27. 27 Wotherspoon, A.C., Doglioni, C., Diss, T.C., et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342 (1993), 575–577.
28. 28 Park, H.S., Kim, Y.J., Yang, W.I., Suh, C.O., Lee, Y.C., Treatment outcome of localized Helicobacter pylori-negative low-grade gastric MALT lymphoma. World J Gastroenterol 16 (2010), 2158–2162.
29. 29 Zackular, J.P., Baxter, N.T., Iverson, K.D., et al. The gut microbiome modulates colon tumorigenesis. MBio 4 (2013), e00692–e00713.
30. 30 Son, J.S., Khair, S., Pettet, D.W., et al. Altered interactions between the gut microbiome and colonic mucosa precede polyposis in APCMin/+ mice. PLoS One, 10, 2015, e0127985.
31. 31 Schwabe, R.F., Jobin, C., The microbiome and cancer. Nat Rev Cancer 13 (2013), 800–812.
32. 32 Zhan, Y., Chen, P.J., Sadler, W.D., et al. Gut microbiota protects against gastrointestinal tumorigenesis caused by epithelial injury. Cancer Res 73 (2013), 7199–7210.
33. 33 Dejea, C.M., Wick, E.C., Hechenbleikner, E.M., et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A 111 (2014), 18321–18326.
34. 34 Johnson, C.H., Dejea, C.M., Edler, D., et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab 21 (2015), 891–897.
35. 35 Wu, G.D., Compher, C., Chen, E.Z., et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut 65 (2016), 63–72.
36. 36 Sesink, A.L., Termont, D.S., Kleibeuker, J.H., Van der Meer, R., Red meat and colon cancer: the cytotoxic and hyperproliferative effects of dietary heme. Cancer Res 59 (1999), 5704–5709.
37. 37 Ijssennagger, N., Belzer, C., Hooiveld, G.J., et al. Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon. Proc Natl Acad Sci U S A 112 (2015), 10038–10043.
38. 38 Rooks, M.G., Garrett, W.S., Gut microbiota, metabolites and host immunity. Nat Rev Immunol 16 (2016), 341–352.
39. 39 Louis, P., Hold, G.L., Flint, H.J., The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 12 (2014), 661–672.
40. 40 Dorrestein, P.C., Mazmanian, S.K., Knight, R., Finding the missing links among metabolites, microbes, and the host. Immunity 40 (2014), 824–832.
41. 41 Matanoski, G., Tao, X., Almon, L., Adade, A.A., Davies-Cole, J.O., Demographics and tumor characteristics of colorectal cancers in the United States, 1998-2001. Cancer 107 (2006), 1112–1120.
42. 42 O'Keefe, S.J., Li, J.V., Lahti, L., et al. Fat, fibre and cancer risk in African Americans and rural Africans. Nat Commun, 6, 2015, 6342.
43. 43 Ou, J., Carbonero, F., Zoetendal, E.G., et al. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. Am J Clin Nutr 98 (2013), 111–120.
44. 44 Cao, H., Luo, S., Xu, M., et al. The secondary bile acid, deoxycholate accelerates intestinal adenoma-adenocarcinoma sequence in Apc (min/+) mice through enhancing Wnt signaling. Fam Cancer 13 (2014), 563–571.
45. 45 Donohoe, D.R., Holley, D., Collins, L.B., et al. A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner. Cancer Discov 4 (2014), 1387–1397.
46. 46 Singh, N., Gurav, A., Sivaprakasam, S., et al. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40 (2014), 128–139.
47. 47 Holmes, E., Li, J.V., Marchesi, J.R., Nicholson, J.K., Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 16 (2012), 559–564.
48. 48 Nicholson, J.K., Holmes, E., Kinross, J., et al. Host-gut microbiota metabolic interactions. Science 336 (2012), 1262–1267.
49. 49 Yoshimoto, S., Loo, T.M., Atarashi, K., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 499 (2013), 97–101.
50. 50 Bindels, L.B., Neyrinck, A.M., Claus, S.P., et al. Synbiotic approach restores intestinal homeostasis and prolongs survival in leukaemic mice with cachexia. ISME J 10 (2016), 1456–1470.
51. 51 Bindels, L.B., Neyrinck, A.M., Salazar, N., et al. Non digestible oligosaccharides modulate the gut microbiota to control the development of leukemia and associated cachexia in mice. PLoS One, 10, 2015, e0131009.
52. 52 Kipanyula, M.J., Seke Etet, P.F., Vecchio, L., Farahna, M., Nukenine, E.N., Nwabo Kamdje, A.H., Signaling pathways bridging microbial-triggered inflammation and cancer. Cell Signal 25 (2013), 403–416.
53. 53 Davis, B.K., Philipson, C., Hontecillas, R., Eden, K., Bassaganya-Riera, J., Allen, I.C., Emerging significance of NLRs in inflammatory bowel disease. Inflamm Bowel Dis 20 (2014), 2412–2432.
54. 54 Vipperla, K., O'Keefe, S.J., Diet, microbiota, and dysbiosis: a “recipe” for colorectal cancer. Food Funct 7 (2016), 1731–1740.
55. 55 Cao, X., Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease. Nat Rev Immunol 16 (2015), 35–50.
56. 56 Renehan, A.G., Zwahlen, M., Egger, M., Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 15 (2015), 484–498.
57. 57 Van Der Kraak, L., Gros, P., Beauchemin, N., Colitis-associated colon cancer: is it in your genes?. World J Gastroenterol 21 (2015), 11688–11699.
58. 58 Liu, J., He, C., Xu, Q., Xing, C., Yuan, Y., NOD2 polymorphisms associated with cancer risk: a meta-analysis. PLoS One, 9, 2014, e89340.
59. 59 Liu, R., Truax, A.D., Chen, L., et al. Expression profile of innate immune receptors, NLRs and AIM2, in human colorectal cancer: correlation with cancer stages and inflammasome components. Oncotarget 6 (2015), 33456–33469.
60. 60 Nigro, G., Rossi, R., Commere, P.H., Jay, P., Sansonetti, P.J., The cytosolic bacterial peptidoglycan sensor Nod2 affords stem cell protection and links microbes to gut epithelial regeneration. Cell Host Microbe 15 (2014), 792–798.
61. 61 Pédron, T., Mulet, C., Dauga, C., et al. A crypt-specific core microbiota resides in the mouse colon. MBio, 3, 2012, 10.1128/mBio.00116-12.
62. 62 Chen, G.Y., Shaw, M.H., Redondo, G., Núñez, G., The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res 68 (2008), 10060–10067.
63. 63 Couturier-Maillard, A., Secher, T., Rehman, A., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 123 (2013), 700–711.
64. 64 Alnabhani, Z., Hugot, J.P., Montcuquet, N., et al. Respective roles of hematopoietic and nonhematopoietic Nod2 on the gut microbiota and mucosal homeostasis. Inflamm Bowel Dis 22 (2016), 763–773.
65. 65 Robertson, S.J., Zhou, J.Y., Geddes, K., et al. Nod1 and Nod2 signaling does not alter the composition of intestinal bacterial communities at homeostasis. Gut Microbes 4 (2013), 222–231.
66. 66 Ayres, J.S., Inflammasome-microbiota interplay in host physiologies. Cell Host Microbe 14 (2013), 491–497.
67. 67 Hu, B., Elinav, E., Huber, S., et al. Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer. Proc Natl Acad Sci U S A 110 (2013), 9862–9867.
68. 68 Levy, M., Thaiss, C.A., Zeevi, D., et al. Microbiota-modulated metabolites shape the intestinal microenvironment by regulating NLRP6 inflammasome signaling. Cell 163 (2015), 1428–1443.
69. 69 Allen, I.C., TeKippe, E.M., Woodford, R.M., et al. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis during colitis-associated cancer. J Exp Med 207 (2010), 1045–1056.
70. 70 Hu, B., Elinav, E., Huber, S., et al. Inflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4. Proc Natl Acad Sci U S A 107 (2010), 21635–21640.
71. 71 Williams, T.M., Leeth, R.A., Rothschild, D.E., et al. The NLRP1 inflammasome attenuates colitis and colitis-associated tumorigenesis. J Immunol 194 (2015), 3369–3380.
72. 72 Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
73. 73 Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43 (2015), 751–763.
74. 74 Man, S.M., Karki, R., Malireddi, R.K., et al. The transcription factor IRF1 and guanylate-binding proteins target activation of the AIM2 inflammasome by Francisella infection. Nat Immunol 16 (2015), 467–475.
75. 75 Meunier, E., Wallet, P., Dreier, R.F., et al. Guanylate-binding proteins promote activation of the AIM2 inflammasome during infection with Francisella novicida. Nat Immunol 16 (2015), 476–484.
76. 76 Man, S.M., Zhu, Q., Zhu, L., et al. Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer. Cell 162 (2015), 45–58.
77. 77 Wilson, J.E., Petrucelli, A.S., Chen, L., et al. Inflammasome-independent role of AIM2 in suppressing colon tumorigenesis via DNA-PK and Akt. Nat Med 21 (2015), 906–913.
78. 78 West, N.R., McCuaig, S., Franchini, F., Powrie, F., Emerging cytokine networks in colorectal cancer. Nat Rev Immunol 15 (2015), 615–629.
79. 79 Grivennikov, S.I., Wang, K., Mucida, D., et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491 (2012), 254–258.
80. 80 Song, X., Gao, H., Lin, Y., et al. Alterations in the microbiota drive interleukin-17C production from intestinal epithelial cells to promote tumorigenesis. Immunity 40 (2014), 140–152.
81. 81 Sundström, P., Ahlmanner, F., Akéus, P., et al. Human mucosa-associated invariant T cells accumulate in colon adenocarcinomas but produce reduced amounts of IFN-γ. J Immunol 195 (2015), 3472–3481.
82. 82 Kjer-Nielsen, L., Patel, O., Corbett, A.J., et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature 491 (2012), 717–723.
83. 83 Ling, L., Lin, Y., Zheng, W., et al. Circulating and tumor-infiltrating mucosal associated invariant T (MAIT) cells in colorectal cancer patients. Sci Rep, 6, 2016, 20358.
84. 84 Deretic, V., Saitoh, T., Akira, S., Autophagy in infection, inflammation and immunity. Nat Rev Immunol 13 (2013), 722–737.
85. 85 Lévy, J., Cacheux, W., Bara, M.A., et al. Intestinal inhibition of Atg7 prevents tumour initiation through a microbiome-influenced immune response and suppresses tumour growth. Nat Cell Biol 17 (2015), 1062–1073.
86. 86 Garrett, W.S., Cancer and the microbiota. Science 348 (2015), 80–86.
87. 87 Geis, A.L., Fan, H., Wu, X., et al. Regulatory T-cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL17-dependent colon carcinogenesis. Cancer Discov 5 (2015), 1098–1109.
88. 88 Housseau, F., Wu, S., Wick, E.C., et al. Redundant innate and adaptive sources of IL-17 production drive colon tumorigenesis. Cancer Res 76 (2016), 2115–2124.
89. 89 DeStefano Shields, C.E., Van Meerbeke, S.W., Housseau, F., et al. Reduction of murine colon tumorigenesis driven by enterotoxigenic Bacteroides fragilis using cefoxitin treatment. J Infect Dis 214 (2016), 122–129.
90. 90 Nougayrède, J.P., Homburg, S., Taieb, F., et al. Escherichia coli induces DNA double-strand breaks in eukaryotic cells. Science 313 (2006), 848–851.
91. 91 Cuevas-Ramos, G., Petit, C.R., Marcq, I., Boury, M., Oswald, E., Nougayrède, J.P., Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc Natl Acad Sci U S A 107 (2010), 11537–11542.
92. 92 Arthur, J.C., Perez-Chanona, E., Mühlbauer, M., et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338 (2012), 120–123.
93. 93 Arthur, J.C., Gharaibeh, R.Z., Mühlbauer, M., et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat Commun, 5, 2014, 4724.
94. 94 Mousa, J.J., Yang, Y., Tomkovich, S., et al. MATE transport of the E. coli-derived genotoxin colibactin. Nature Microbiology, 1, 2016, 15009.
95. 95 Yang, Y., Jobin, C., Microbial imbalance and intestinal pathologies: connections and contributions. Dis Model Mech 7 (2014), 1131–1142.
96. 96 Kostic, A.D., Chun, E., Robertson, L., et al. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14 (2013), 207–215.
97. 97 Gur, C., Ibrahim, Y., Isaacson, B., et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42 (2015), 344–355.
98. 98 Mima, K., Sukawa, Y., Nishihara, R., et al. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 1 (2015), 653–661.
99. 99 Kirchberger, S., Royston, D.J., Boulard, O., et al. Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model. J Exp Med 210 (2013), 917–931.
100. 100 Zitvogel, L., Galluzzi, L., Viaud, S., et al. Cancer and the gut microbiota: an unexpected link. Sci Transl Med, 7, 2015, 271ps1.
101. 101 Bultman, S.J., The microbiome and its potential as a cancer preventive intervention. Semin Oncol 43 (2016), 97–106.
102. 102 Belcheva, A., Irrazabal, T., Martin, A., Gut microbial metabolism and colon cancer: can manipulations of the microbiota be useful in the management of gastrointestinal health?. Bioessays 37 (2015), 403–412.
103. 103 Ambalam, P., Raman, M., Purama, R.K., Doble, M., Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol 30 (2016), 119–131.
104. 104 Chemo side effects. Available at: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/understandingchemotherapyaguideforpatientsandfamilies/understanding-chemotherapy-chemo-side-effects. Accessed April 6, 2016.
105. 105 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Available at: http://clincancerres.aacrjournals.org/content/7/8/2182.full.pdf+html. Accessed March 27, 2016.
106. 106 Mori, K., Kondo, T., Kamiyama, Y., Kano, Y., Tominaga, K., Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51 (2003), 403–406.
107. 107 Fittkau, M., Voigt, W., Holzhausen, H.J., Schmoll, H.J., Saccharic acid 1.4-lactone protects against CPT-11-induced mucosa damage in rats. J Cancer Res Clin Oncol 130 (2004), 388–394.
108. 108 Roberts, A.B., Wallace, B.D., Venkatesh, M.K., Mani, S., Redinbo, M.R., Molecular insights into microbial β-glucuronidase inhibition to abrogate CPT-11 toxicity. Mol Pharmacol 84 (2013), 208–217.
109. 109 Kong, R., Liu, T., Zhu, X., et al. Old drug new use–amoxapine and its metabolites as potent bacterial β-glucuronidase inhibitors for alleviating cancer drug toxicity. Clin Cancer Res 20 (2014), 3521–3530.
110. 110 Wallace, B.D., Roberts, A.B., Pollet, R.M., et al. Structure and inhibition of microbiome β-glucuronidases essential to the alleviation of cancer drug toxicity. Chem Biol 22 (2015), 1238–1249.
111. 111 Lin, X.B., Farhangfar, A., Valcheva, R., et al. The role of intestinal microbiota in development of irinotecan toxicity and in toxicity reduction through dietary fibres in rats. PLoS One, 9, 2014, e83644.
112. 112 Paci, A., Veal, G., Bardin, C., et al. Review of therapeutic drug monitoring of anticancer drugs part 1–cytotoxics. Eur J Cancer 50 (2014), 2010–2019.
113. 113 Frank, M., Hennenberg, E.M., Eyking, A., et al. TLR signaling modulates side effects of anticancer therapy in the small intestine. J Immunol 194 (2015), 1983–1995.
114. 114 Mellman, I., Coukos, G., Dranoff, G., Cancer immunotherapy comes of age. Nature 480 (2011), 480–489.
115. 115 Vétizou, M., Pitt, J.M., Daillère, R., et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350 (2015), 1079–1084.
116. 116 Dubin, K., Callahan, M.K., Ren, B., et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun, 7, 2016, 10391.
117. 117 Lehouritis, P., Cummins, J., Stanton, M., et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep, 5, 2015, 14554.
118. 118 Sistigu, A., Viaud, S., Chaput, N., Bracci, L., Proietti, E., Zitvogel, L., Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 33 (2011), 369–383.
119. 119 Viaud, S., Saccheri, F., Mignot, G., et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science 342 (2013), 971–976.
120. 120 Iida, N., Dzutsev, A., Stewart, C.A., et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 342 (2013), 967–970.
121. 121 Gui, Q.F., Lu, H.F., Zhang, C.X., Xu, Z.R., Yang, Y.H., Well-balanced commensal microbiota contributes to anti-cancer response in a lung cancer mouse model. Genet Mol Res 14 (2015), 5642–5651.
122. 122 Sivan, A., Corrales, L., Hubert, N., et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350 (2015), 1084–1089.
123. 123 Goto, Y., Panea, C., Nakato, G., et al. Segmented filamentous bacteria antigens presented by intestinal dendritic cells drive mucosal Th17 cell differentiation. Immunity 40 (2014), 594–607.